Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for February 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Mental Health Disorders Up After Head & Neck Cancer Diagnosis
THURSDAY, Feb. 28, 2019 (HealthDay News) — In patients with head and neck cancer (HNC), the prevalence of mental health disorders (MHDs) is significantly higher after cancer diagnosis, according to a study published online Feb. 28 in JAMA Otolaryngology-Head & Neck Surgery.
Robotically Assisted Devices Not Approved for Cancer Surgery
THURSDAY, Feb. 28, 2019 (HealthDay News) — The use of robotically assisted surgical devices for breast removal and other cancer-related surgeries is not approved by the U.S. Food and Drug Administration because there is no proof of its safety or effectiveness in such cases, the agency says in a warning to doctors and patients.
Performance Improvement Sustained After DBT Adoption
THURSDAY, Feb. 28, 2019 (HealthDay News) — Performance improvements after adoption of digital breast tomosynthesis (DBT) relative to digital mammography (DM) performance have been sustained, regardless of DBT volume, according to a study published online Feb. 26 in Radiology.
Intervention Can Reduce Racial Differences in Lung Cancer Care
THURSDAY, Feb. 28, 2019 (HealthDay News) — An intervention that includes race-specific feedback and real-time electronic warnings can reduce racial differences in care for early-stage lung cancer, according to a study published online Feb. 4 in Cancer Medicine.
Lymphadenectomy Does Not Up Survival in Advanced Ovarian Cancer
WEDNESDAY, Feb. 27, 2019 (HealthDay News) — For patients with advanced ovarian cancer who have undergone intra-abdominal macroscopically complete resection and have clinically negative lymph nodes, lymphadenectomy is not associated with longer overall or progression-free survival, according to a study published in the Feb. 28 issue of the New England Journal of Medicine.
Adjuvant Tx for Early Testicular Cancer Does Not Harm Sperm
WEDNESDAY, Feb. 27, 2019 (HealthDay News) — For clinical stage I testicular cancer (TC) patients, adjuvant treatment after orchiectomy has no long-term significant effect on sperm production, according to a study published online Feb. 25 in the Annals of Oncology.
Decline Observed in HPV Type 16/18 Cervical Precancers in U.S.